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MaOBJECTIVES The purpose of this study was to identify the relationship of B-type natriuretic peptide (BNP) with
evolution of left ventricular mass (LVM) in optimally treated primary prevention patients.
BACKGROUND Patients who have an elevated BNP no cardiac abnormality on echocardiography are common and at
increased risk of adverse events. One hypothesis is that an elevated BNP is an early sensitive indicator of who will develop
future structural abnormalities such as left ventricular (LV) hypertrophy.
METHODS We identiﬁed optimally treated primary prevention patients with no cardiac abnormality at baseline. In
particular, they had no myocardial ischemia, LV hypertrophy, LV dysfunction, or left atrial enlargement. They had a
diverse range of plasma BNP levels and underwent cardiac magnetic resonance at baseline and 3 years later on a 3-T
scanner.
RESULTS Fifty patients with a diverse range of BNP were studied (with BNP #10 pg/ml in 25 patients and >10 pg/ml
in 25 patients). LVM increased (þ4.7  3.5 g) in 24 patients and decreased (–4.9  2.8 g) in 26 patients (p < 0.01).
Blood pressure by 24-h monitoring was virtually identical between those whose LVM increased (systolic blood pressure
122  14 mm Hg) and those whose LVM decreased (systolic blood pressure 121  11 mm Hg, p ¼ 0.77). Plasma BNP
was nearly 3 times higher in those whose LVM increased versus those in whom LVM decreased (21  9.6 pg/ml vs.
7.9  3.9 pg/ml, p < 0.01). The c-statistic for BNP was 0.88.
CONCLUSIONS In optimally treated primary prevention patients, plasma BNP levels are able to distinguish between
those whose LVM will increase during the next 3 years versus those whose LVM will decrease during the next 3 years. This
may explain why individuals with high BNP are at increased risk even if no cardiac abnormality can be detected
initially. (J Am Coll Cardiol HF 2015;3:87–93) © 2015 by the American College of Cardiology Foundation. 
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ABBR EV I A T I ON S
AND ACRONYMS
ACE = angiotensin-converting
enzyme
ARB = angiotensin receptor
blocker
BNP = B-type natriuretic
peptide
BP = blood pressure
CMR = cardiac magnetic
resonance
CV = cardiovascular
eGFR = estimated glomerular
ﬁltration rate
hs-TnT = high-sensitivity
troponin T
LV = left ventricular
LVEDV = left ventricle
end-diastolic volume
LVESV = left ventricular
end-systolic volume
LVH = left ventricular
hypertrophy
LVM = left ventricular mass
LVMI = left ventricular mass
index
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88of those in the highest tertile of BNP have
no apparent cardiac abnormality on pheno-
typing (1).
BNP is known to be a very strong inde-
pendent predictor of a poor (cardiac) prog-
nosis in every population ever examined
(2–7). This even seems to be the case in in-
dividuals with high BNP levels but no ap-
parent cardiac abnormality on phenotyping
(false positives). Several studies show that
BNP levels predict prognosis over and above
a wide range of baseline echocardiographic
abnormalities, although, as would be ex-
pected, each echocardiographic abnormality
explained part of the BNP risk (4–7).
The unexplained extra BNP risk not
accounted for by echocardiographic abnor-
malities may be related to BNP being able to
predict future but not yet apparent abnor-
malities in left ventricular (LV) structure or
function (5,8). The hypothesis that these
data raise is that one of the drivers for future
LV abnormalities is intracardiac pressure and
that an early subtle elevation in intracardiac
pressure can be picked up by BNP before LV
abnormalities are either present or detect-able on imaging. We therefore set out to see whether
in individuals with no apparent cardiac abnormality
at baseline a high BNP value could identify those who
would develop a cardiac abnormality during the next
few years. We focused particularly on left ventricular
mass (LVM) to see whether BNP predicted how this
would change during the next few years in a popu-
lation of treated primary prevention patients.
METHODS
STUDY POPULATION. This is a substudy of a previ-
ously reported larger study from our center (1). The
original study recruited 300 primary prevention pa-
tients with well-treated primary risk factors between
April 2008 and July 2010 from local general practi-
tioner surgeries and from the cardiovascular (CV)
risk clinic at Ninewells Hospital, Dundee, United
Kingdom. Patients included in the original study were
50 years or older, and were eligible for primary pre-
vention only with no previous known CV events.
They had to be stable on therapy for at least 1 year and
to have reached target for their primary risk factor, for
example, ofﬁce blood pressure (BP) #140/90 mm Hg.
We excluded those with previously known CV dis-
ease, known renal impairment (estimated glomerular
ﬁltration rate [eGFR] <60 ml/min), atrial ﬁbrillation,
and signiﬁcant (deﬁned as more than mild) valvularheart disease. All study subjects underwent clinical
assessment, biochemical measurements (including
BNP), electrocardiography, transthoracic echocardi-
ography, dobutamine stress echocardiography to
detect myocardial ischemia, and 24-hour ambulatory
BP measurement.
From the original cohort of 300 primary prevention
patients, 62 patients underwent baseline cardiac
magnetic resonance (CMR) and 50 of them completed
a second CMR after a mean follow-up of 3 years.
These 62 patients were selected for 2 reasons: 1)
freedom from any silent cardiac target organ damage
in the form of either left ventricular hypertrophy
(LVH), LV diastolic or systolic impairment, left atrial
enlargement, and inducible myocardial ischemia; and
2) a wide range of baseline BNP levels. The reasons for
12 patients having no second CMR scan are shown in
Online Figure 1.
BIOCHEMICAL ASSAYS. Biochemical measurements
including BNP and high-sensitivity troponin T (hs-
TnT) were made by trained laboratory staff blinded
to the clinical and echocardiographic data. BNP was
measured using Triage BNP assay (Biosite Inc., San
Diego, California). The interassay percentage coefﬁ-
cient of variation was 8.8% to 11.6%. The detection
limit was 5 pg/ml and upper measuring limit was
5,000 pg/ml. hs-TnT was measured using a highly
sensitive assay on an automated platform (Elecsys
E170, Roche Diagnostics, Indianapolis, Indiana) with
lower limit of blank (3 ng/l) and interassay percentage
coefﬁcient of variation #10%.
CARDIAC MAGNETIC RESONANCE. Cardiac magnetic
resonance was performed at baseline and at 36
months on a 3-T Magnetom Trio scanner (Siemens,
Erlangen, Germany) using body array and spine ma-
trix radiofrequency coils as described in detail pre-
viously (9,10). CMR images were analyzed ofﬂine by
an independent, blinded, magnetic resonance physi-
cist (S.J.G.) using commercial software (Argus,
Siemens Multi-modality Work Platform, version VB
15, Siemens). Electronic region-of-interest contours
were placed around endocardial and epicardial LV
borders on all CMR image slices at end-diastole and
end-systole that were identiﬁed to contain 50% or
more full-thickness myocardium. Papillary muscles
were included in the LVM if the muscle structure
was indistinguishable from the myocardial wall, but
otherwise assigned to the LV blood pool. The process
of contour placement was repeated such that every
patient dataset at both time points was analyzed
twice to optimize the measurement precision. The
intraobserver variability was 2.02% at baseline and
1.97% at follow-up.
TABLE 1 Characteristics of Study Population Stratiﬁed by Change in LVM
(n ¼ 50)
Variable
LVM Decreased
(n ¼ 26)
LVM Increased
(n ¼ 24) Signiﬁcance*
Age (yrs) 63.8  6.1 61.5  4.1 0.39
Male/female 18/8 (69%/31%) 14/10 (58%/42%) 0.39
Hypertensive 24 (92%) 19 (80%) 0.40
Dyslipidemia 19 (73%) 12 (50%) 0.08
Duration of treatment (yrs) 3.5  2.4 4.3  4.7 0.55
Smoker 3 (12%) 10 (41%) 0.02
Family history of cardiovascular disease 15 (58%) 16 (67%) 0.55
BMI (kg/m2) 26.6  4.0 27.5  3.0 0.19
SBP (mm Hg) 121  11 122  14 0.77
DBP (mm Hg) 73  7 74  6 0.45
Baseline 10-yr CVD risk (Framingham) 18.6  9.1 21.1  10.0 0.35
Baseline QRISK2 21.9  9.5 20.5  9.1 0.67
Creatinine (mmol/l) 79.2  13.7 74.6  13.9 0.85
Creatinine clearance (ml/min) 90.6  22.0 97.9  25.0 0.15
eGFR (ml/min/1.73 m2) 86.3  15.0 87.5  16.0 0.65
Total cholesterol (mmol/l) 4.5  1.0 5.5  0.8 0.008
HDL (mmol/l) 1.6  0.4 1.6  0.5 0.82
Uric acid (mmol/l) 0.41  0.1 0.44  0.1 0.08
BNP (pg/ml) 7.9  3.8 21.0  9.6 0.0001
hs-TnT (ng/l) 4.9  2.1 6.9  2.4 0.04
ACEi 12 (46%) 13 (54%) 0.41
ARB 8 (31%) 6 (25%) 0.51
Diuretics 10 (38%) 8 (33%) 0.88
Beta-blockers 5 (19%) 3 (12%) 0.49
Ca2þ channel blockers 10 (38%) 9 (37%) 0.86
Statins 16 (61%) 12 (50%) 0.38
Transmitral E/A 0.83  0.20 0.84  0.18 0.93
Transmitral E/e0 9.4  2.1 9.7  2.6 0.62
CMR baseline LVM 108  21 103  26 0.50
CMR baseline LVM index 56  8 54  9 0.54
CMR LVEF (%) 75.3  5.0 75.8  4.7 0.76
CMR LVEDV 122  23 118  33 0.13
CMR LVESV 31  10 29  11 0.30
Follow-up time (months) 36.2  0.3 36.5  1.2 0.42
Values are mean  SD or n (%). *Student t test, Chi-square, Fisher exact test, or Mann-Whitney U test.
ACEi ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; BMI ¼ body mass index;
BNP ¼ B-type natriuretic peptide; CMR ¼ cardiac magnetic resonance; CVD ¼ cardiovascular disease; DBP ¼
diastolic blood pressure; E/A ¼ ratio of the early to late ventricular ﬁlling velocities; E/e0 ¼ ratio of the early
diastolic transmitral ﬂow velocity to the mitral annular velocity; eGFR ¼ estimated glomerular ﬁltration rate;
HDL ¼ high-density lipoprotein; hs-TnT ¼ high-sensitivity troponin T; LVEDV ¼ left ventricular end-diastolic
volume; LVEF ¼ left ventricular ejection fraction; LVESV ¼ left ventricular end-systolic volume; LVM ¼ left
ventricular mass; SBP ¼ systolic blood pressure.
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89STATISTICAL METHODS. Data for continuous vari-
ables are presented as mean  SD for normally
distributed data and median and interquartile range
for nonnormally distributed data. Categorical data are
expressed as numbers (%). Comparisons between
continuous variables were analyzed using the Stu-
dent t test or Mann-Whitney U test, whereas cate-
gorical variables were analyzed using chi-square test
or Fisher exact test. The primary outcome measure
was change in left ventricular mass (DLVM) from
baseline to follow-up at 3 years. The study population
was divided into 2 groups depending on the rise or
fall in LVM at follow-up compared with the LVM at
baseline. We also divided the study cohort into ter-
tiles based on BNP levels according to a prespeciﬁed
protocol in 2 ways. The ﬁrst was by dividing the 50
patients into the cohort’s own BNP tertiles. The sec-
ond was to use the tertile BNP levels of the original
300 patients: this latter approach was used to avoid
bias in the way the patients in this substudy were
selected from the full cohort (n ¼ 300). The signiﬁ-
cance level for the trend across the tertiles was
calculated by Jonckheere-Terpstra test and chi-
square test. Multivariable models were used to
identify the predictors of DLVM and to calculate
c-statistics, and area under the curve was compared
by the DeLong method. All statistical analyses were
performed using SPSS for Windows version 20.0 (IBM
Corp, Armonk, New York), and a 2-sided probability
value of <0.05 was considered to be signiﬁcant. The
Tayside Research and Ethics Committee approved
the research protocol, and all study participants pro-
vided written informed consent.
RESULTS
BASELINE CHARACTERISTICS OF STUDY POPULATION.
The baseline characteristics of all 50 patients (mean
age 64 years, 64% male) are shown in Online Tables 1
and 2. The primary risk factor was hypertension in 43
of 50 (86%) of patients, whereas 31 of 50 (62%) had a
history of dyslipidemia. On average all patients had
received treatment for their primary risk factor for
greater than 3 years at the time of recruitment and
were clinically stable with no overt cardiac symp-
toms. The majority of the patients were on antihy-
pertensive therapy and greater than two-thirds
(39 of 50) received either an angiotensin-converting
enzyme (ACE) inhibitor or an angiotensin receptor
blocker (ARB). Baseline BP assessment by ambulatory
BP recording revealed good BP control (mean BP
119/72 mm Hg), whereas 56% (28 of 50) of the study
patients also received a statin. Online Table 2 also
shows that the 50 patients without target organdamage who received a CMR were virtually identical
to the 148 patients in our index study who also had no
target organ damage at baseline and did not undergo
CMR at follow-up (1).
CMR DATA. Fifty patients completed the follow-up
CMR scan, and mean follow-up was 36.3  0.9
months. The average LVM at baseline was 105  24 g
and 55  9 g/m2 when indexed to body surface area.
At follow-up, LVM measured lower than baseline
(mean D –4.9  2.8 g) in 52% (26 of 50), whereas an
increase (mean D 4.7  3.5 g) in LVM was seen in 48%
(24 of 50) patients. Clinical characteristics of patients
TABLE 2 Changes in CMR Data According to Baseline BNP Tertiles*
CMR Variable
Tertile I
(n ¼ 16)
Tertile II
(n ¼ 17)
Tertile III
(n ¼ 17) p Value† pTREND‡
Change in LVM –5.14  2.64 –1.60  4.67 5.49  3.78 0.0001 0.0001
% Change in LVM –5.04  2.62 –1.16  4.36 5.50  3.79 0.0001 0.0001
Change in LVM Index –2.92  2.20 –0.98  0.96 3.10  2.87 0.0001 0.0001
% Change in LVM index –5.24  4.05 –1.80  1.82 5.97  4.77 0.0001 0.0001
Change in LVEF (%) –0.18  4.86 –1.15  3.39 1.04  2.83 0.28 0.38
Change in LVESV 1.31  7.45 0.43  5.40 –1.58  4.01 0.53 0.37
Change in LVEDV 3.5  11.2 –2.68  10.18 –2.8  10.90 0.33 0.35
Values are mean  SD. *Tertiles for n ¼ 50: Tertile I 5.0 to 6.4 pg/ml, Tertile II 6.9 to 15.5 pg/ml, Tertile III 18.6
to 37.5 pg/ml. †Kruskal-Wallis test. ‡Jonckheere-Terpstra test.
Abbreviations as in Table 1.
FIGURE 1 Distribu
Red dots represent B
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90with a reduction and an increase in LVM are shown
in Table 1, and the change in LV data on CMR are
summarized in Table 2. Not surprisingly, LV ﬁlling
(LV end-diastolic volume) was reduced in those
whose LVM increased with time.
No signiﬁcant differences were noticed in de-
mographics and prevalence of underlying primary
risk factor(s) between the 2 groups except that the
patients in whom an increase in LVM was observed
were signiﬁcantly more likely to be active smokers
(41% vs. 12%, p ¼ 0.02) or have higher cholesterol
levels (5.5  0.8 vs. 4.5  1.0, p < 0.01). No signiﬁcant
differences were noticed in baseline BP as assessed
by 24-h ambulatory BP monitoring, underlying renal
function, or baseline pharmacotherapy, and baseline
LVM was also similar in both groups at baseline
(Table 1). The baseline diastolic parameters ontion of Baseline BNP and hs-TnT Levels Across the Range of DLVM
-type natriuretic peptide (BNP) and blue dots represent high-
(hs-TnT). DLVM ¼ change from baseline in left ventricular (LV) mass.2-dimensional echocardiography, including the ratio
of the early diastolic transmitral ﬂow velocity (E) to
the mitral annular velocity (e0), or transmitral E/e0,
were not statistically different between those with
or without a future rise in LVM.
BNP AND HIGH SENSITIVITY CARDIAC TROPONIN T
AND CHANGE IN LVM. Both BNP (mean BNP 21 vs.
7.9 pg/ml) and hs-TnT (mean hs-TnT 6.9 vs. 4.9 ng/l)
levels at baseline were signiﬁcantly higher in patients
whose LVM increased with time (Table 1). There was
no signiﬁcant effect of age or sex on this observation.
Among all the CMR parameters, only LVM and LVM
index (LVMI) changed signiﬁcantly according to
baseline BNP values (Online Table 3). Correlation
analysis showed a strong linear relationship (r ¼ 0.71,
p < 0.01) between DLVM and baseline BNP levels
(Figure 1) There was a strong positive relationship
between BNP tertiles and DLVM (Figure 2, Online
Table 3). This was the case whether the BNP tertiles
were calculated on the basis of the tertiles of the
original study (n ¼ 300) or the tertiles of this substudy
(n ¼ 50) (Figure 2). It is worth noting that the differ-
ence between tertile 1 and tertile 3 is large at nearly
12% of the mean baseline LVMI.
The independent predictive value of the interac-
tion between DLVM and baseline BNP levels for
explaining the evolution of LVM with time (depen-
dent variable) was investigated by multiple linear
regression analysis. We investigated 5 different
models (Table 3). Model 1 was composed of previously
reported clinical predictors of LVM such as age, sex,
BP, body mass index, and history of smoking. Sub-
sequent models explored the additional predictive
value of adding total cholesterol and uric acid and
then adding baseline hs-TnT or BNP on top of model 1.
As shown in Table 3, both hs-TnT and BNP offered
additional predictive value when added to the model
by improving the c-statistics signiﬁcantly. In a logistic
regression analysis, BNP stood out as a strong pre-
dictor of a future rise in LVM. A receiver-operating
characteristic analysis yielded a c-statistic of 0.88
for BNP with a sensitivity and speciﬁcity of 70%
and 88%, respectively, at a BNP level of 17 pg/ml.
DISCUSSION
Our main ﬁnding is that, in well-controlled primary
prevention patients, a high BNP in the absence of any
cardiac abnormality is able to identify those in-
dividuals whose LVM will increase during the next
3 years, that is, an elevated BNP is able to predict
future increases in LVM. This may partly explain why,
in so many studies, BNP predicts prognosis indepen-
dent of echocardiographic abnormalities.
FIGURE 2 DLVM Across the BNP Tertiles
The top diagram (A) uses the BNP tertile levels of this n ¼ 50
cohort; the lower diagram (B) uses the BNP tertile levels of the
original larger n ¼ 300 cohort (1). Tertiles for n ¼ 50: tertile I 5 to
6.40 pg/ml, tertile II 6.9 to 15.5 pg/ml, tertile III 18.6 to 37.5 pg/ml.
BSA ¼ body surface area; LVM ¼ left ventricular (LV) mass.
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91The Framingham study has already shown that the
tendency for LVM to increase with aging in a popu-
lation is highly variable from one individual to the
next (11,12). Increases in LVM in treated hypertension
are, however, far from innocent (13). Serial changes in
LVM predict CV events, independent of baseline LVM
and independent of baseline BP or the degree of BP
reduction (14). It now appears from our data that BNP
can identify those whose serial LVM will increase
with time, and we know that such individuals are at
increased risk and that they are currently inade-
quately identiﬁed by either baseline LVM or any BP
parameter (14).
A major strength of our study is that the population
studied was comprehensively phenotyped atbaseline, that is, they were all assessed for LVM, LV
systolic dysfunction, left atrial enlargement, LV dia-
stolic dysfunction, and most importantly, for silent
myocardial ischemia. All 5 of these abnormalities are
known to increase BNP and to herald a poor prognosis
(1,15). However we know with certainty that in the
population we studied here, none of these cardiac
abnormalities were present at baseline, meaning that
the BNP elevation at baseline was truly unexplained
by any prevalent cardiac abnormality. This makes our
study unique as most data on BNP being of prognostic
signiﬁcance over and above echocardiographic ab-
normalities did not do the comprehensive phenotyp-
ing that we did and in particular did not screen for
myocardial ischemia, which is known to indepen-
dently increase BNP (4–7,16). In previous studies,
some of the prognostic signiﬁcance of BNP over and
above resting echocardiographic abnormalities could
be attributable to silent myocardial ischemia, which
was not tested for in those studies. However, we have
here demonstrated an additional explanation for why
BNP is prognostic beyond echocardiographic abnor-
malities at baseline, which is that baseline BNP can
identify those whose LVM will increase with time.
A lot of recent data are suggesting that measuring
BNP might one day establish a role for itself in
better managing patients with treated hypertension
(2). Paget et al. showed that there was a 3-fold in-
crease in mortality in the top versus the bottom
tertile of N-terminal pro-BNP in treated hyperten-
sive patients, even after adjusting for traditional risk
factors (2). Recent information from the ASCOT trial
shows the same (17). These 2 papers suggest that
BNP could become a measure within individuals at
target BP of whether antihypertensive therapy will
actually prevent CV events in them or not. In turn,
this begs the question of which (treatable) cardiac
abnormalities might be causing the residual risk
seen in treated hypertensive patients with a high
BNP. Nadir et al. answered that question by showing
that treated hypertensive patients with a high BNP
had a combination of LVH, LV diastolic dysfunction,
LA enlargement, LV systolic dysfunction, and silent
ischemia (in that order of frequency) (1). Impor-
tantly, many patients had multiple silent cardiac
abnormalities. This study extends that information
to now show that in those with no cardiac abnor-
mality at baseline, the elevated residual risk iden-
tiﬁed by BNP is likely to be also related to future
increases in LVM (18,19).
There are a few likely explanations for our results.
A time effect is likely in that a raised intracardiac
pressure genuinely precedes the increase in LVM.
BNP is a much more sensitive marker for this
TABLE 3 Multivariate Prediction Models for Evolution of LVM
Model c-statistics* p Value*
Model 1: age, sex, SBP, BMI, and smoking 0.72 Model 1 vs. Model 2, p ¼ 0.32
Model 2: age, sex, SBP, BMI, smoking,
uric acid, and total cholesterol
0.76 Model 1 vs. Model 3, p ¼ 0.11
Model 1 vs. Model 4, p ¼ 0.0007
Model 3: age, sex, SBP, BMI, smoking,
uric acid, cholesterol, and troponin
0.83 Model 1 vs. Model 5, p ¼ 0.0009
Model 2 vs. Model 3, p ¼ 0.27
Model 2 vs. Model 4, p ¼ 0.001
Model 4: age, sex, SBP, BMI, smoking,
uric acid, cholesterol, and BNP
0.98 Model 2 vs. Model 5, p ¼ 0.002
Model 3 vs. Model 4, p ¼ 0.01
Model 5: age, sex, SBP, BMI, smoking,
uric acid, cholesterol, troponin, and BNP
0.98 Model 3 vs. Model 5, p ¼ 0.01
Model 4 vs. Model 5, p ¼ 0.01
*Pairwise comparison between the various models by DeLong method.
Abbreviations as in Table 1.
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92increased intracardiac pressure owing to its greater
reproducibility of repeat measures and a greater
measurement range, whereas imaging parameters
change over a much smaller range. This means an
early subtle elevation in intracardiac pressure can be
picked up by BNP before LV abnormalities are either
present or detectable on imaging. Although it is also
plausible that an elevated BNP marker could merely
be a marker of noncompliance, it is important to note
that our study population had well-controlled pri-
mary risk factor at the baseline.
At this time, there are clearly no therapeutic impli-
cations for this work, but looking to the future, there
could be. For example, aggressive risk factor control
guided by BNP levels may prevent future development
of LVH and by doing so it may even prevent a future CV
event itself. The expression “Prevention is better than
cure” is highly relevant here because a life-changing
CV event related to LVH (such as a stroke or even
sudden death) could occur while there is LVH before
its regression is achieved, and full regression does not
always occur anyway. The treatments that are known
to regress established LVH in a normotensive patient
(e.g., a lower target BP, aldosterone blockade) might
one day be useful to prevent LVH from developing in
susceptible patients already at target BP (20,21). This
notion of using BNP-guided aggressive risk factor
control to prevent future CV events is supported by
the results of the STOP-HF trial (22). In this trial a 42%
relative risk reduction in the development of LV sys-
tolic dysfunction (with or without overt heart failure)
was seen with intensiﬁcation of therapy in patients
with CV risk factors and a BNP >50 pg/ml. Moreover,
it is also conceivable that the use of novel CMR tech-
niques to characterize the underlying tissue changes
seen in the evolution of LVM may help to identify
new therapeutic targets in future.
STUDY LIMITATIONS. As ever, there are limitations
to our study. The number of individuals is relativelylow (n ¼ 50); however, it uses CMR scanning, which
is more sensitive than echocardiography. In fact, the
mean difference between the top and bottom BNP
tertiles at the end of 3 years was fairly large, nearly
12% of baseline LVMI. Moreover, this is a longitudi-
nal study of the same individuals over time, which is
more informative at understanding natural history
than commonly performed cross-sectional studies.
Second, the fact that we preselected patients across
a relatively wide range of BNP values at baseline
with no serial measurements with time may have
ﬂattered our results, although this was not an un-
reasonable approach to maximize the cost-
effectiveness of our study because our primary aim
or hypothesis was to see how individuals with high
BNP levels differed over time from individuals with
low BNP levels. This selection limitation is assuaged
by 2 factors. First, the demography of our chosen
cohort was virtually identical to the demography of
the patients in our index study who had no target
organ damage at baseline. Second, we used BNP
tertiles from our index as well as the current study.
These 2 added analyses strongly suggest that selec-
tion bias did not inﬂuence our results, although
future research with larger numbers would be
required to conﬁrm these ﬁndings. Finally, BNP (and
hs-TnT) levels seen in our study (not unexpectedly)
are at the lower end of the range, and imprecision of
the assay may be relevant at these levels.
CONCLUSIONS
It now appears that optimally treated hypertensive
patients with a top tertile BNP but a normal echocar-
diographic study are likely to experience an increase
in LVM. This may in part explain why patients with
high BNP levels and a normal echocardiographic study
have a poor prognosis, including why they often
experience atrial ﬁbrillation and heart failure. The
next stage would be tissue characterization with novel
CMR techniques in the evolution of LVM and to see
whether treatments that are known to regress estab-
lished LVH can actually prevent LVH from developing
in those identiﬁed to be at high risk by their having
an otherwise unexplained high BNP.
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